Dennis Mulroy - Sep 14, 2024 Form 4 Insider Report for ANAPTYSBIO, INC (ANAB)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/ Eric Loumeau, Attorney-in-Fact
Stock symbol
ANAB
Transactions as of
Sep 14, 2024
Transactions value $
-$286,125
Form type
4
Date filed
9/17/2024, 06:41 PM
Previous filing
Jul 24, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANAB Common Stock Options Exercise +6K +622.41% 6.96K Sep 14, 2024 Direct F1
transaction ANAB Common Stock Sale -$86.4K -2.22K -31.88% $38.93 4.74K Sep 16, 2024 Direct F2
transaction ANAB Common Stock Options Exercise $202K +10K +210.79% $20.16 14.7K Sep 16, 2024 Direct
transaction ANAB Common Stock Sale -$401K -10K -67.82% $40.13 4.74K Sep 16, 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANAB Restricted Stock Unit Options Exercise $0 -6K -100% $0.00 0 Sep 14, 2024 Common Stock 6K Direct F1, F4
transaction ANAB Employee Stock Option (right to buy) Options Exercise $0 -10K -11.04% $0.00 80.6K Sep 16, 2024 Common Stock 10K $20.16 Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2 The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F3 The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated June 14, 2024.
F4 50% of the total restricted stock units vested on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F5 The stock option vests and becomes exercisable as to 25% of the shares subject to the option on July 15, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
F6 In addition to the remaining options to purchase 80,600 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 263,040 shares of common stock, which options vest according to their terms.